BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31603365)

  • 21. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
    Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T
    PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88
    Kida T; Tanimura A; Ono A; Matsui T; Honma K; Fujita J; Maeda T; Shibayama H; Oritani K; Morii E; Kanakura Y
    Rinsho Ketsueki; 2017; 58(2):155-160. PubMed ID: 28321094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic efficacy of cell block method for vitreoretinal lymphoma.
    Kase S; Namba K; Iwata D; Mizuuchi K; Kitaichi N; Tagawa Y; Okada-Kanno H; Matsuno Y; Ishida S
    Diagn Pathol; 2016 Mar; 11():29. PubMed ID: 26987877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
    Martinez-Lopez A; Curiel-Olmo S; Mollejo M; Cereceda L; Martinez N; Montes-Moreno S; Almaraz C; Revert JB; Piris MA
    Am J Surg Pathol; 2015 May; 39(5):644-51. PubMed ID: 25723115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F
    JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
    Nishimura N; Takeuchi K; Asaka R; Tuyama N; Inoue N; Kusano Y; Mishima Y; Yokoyama M; Terui Y
    Leuk Res; 2020 Oct; 97():106426. PubMed ID: 32781214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring : ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation.
    Drandi D; Ferrante M; Borriero M; Ferrero S
    Methods Mol Biol; 2023; 2621():57-72. PubMed ID: 37041440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
    Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
    BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-Generation Sequencing of Vitreoretinal Lymphoma by Vitreous Liquid Biopsy: Diagnostic Potential and Genotype/Phenotype Correlation.
    Kwak JJ; Lee KS; Lee J; Kim YJ; Choi EY; Byeon SH; Chang WS; Kim YR; Kim JS; Shin S; Lee ST; Kim SS; Lee CS
    Invest Ophthalmol Vis Sci; 2023 Nov; 64(14):27. PubMed ID: 37975847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
    Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
    Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring of MYD88 L265P mutation by droplet digital polymerase chain reaction for prediction of early relapse in a patient with Bing-Neel syndrome.
    Shikata H; Kihara H; Kaneko M; Matsukage S; Hattori K
    Int J Hematol; 2021 Apr; 113(4):586-591. PubMed ID: 33222046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.
    Poulain S; Boyle EM; Roumier C; Demarquette H; Wemeau M; Geffroy S; Herbaux C; Bertrand E; Hivert B; Terriou L; Verrier A; Pollet JP; Maurage CA; Onraed B; Morschhauser F; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
    Br J Haematol; 2014 Nov; 167(4):506-13. PubMed ID: 25160558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
    Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
    Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma.
    Carbonell D; Mahajan S; Chee SP; Sobolewska B; Agrawal R; Bülow T; Gupta V; Jones NP; Accorinti M; Agarwal M; Batchelor T; Biswas J; Cimino L; tenDam-van Loon NH; de-la-Torre A; Frenkel S; Pe'er J; Kramer M; Miserocchi E; Mochizuki M; Ness T; Rosenbaum JT; Sen HN; Simion M; Sitter H; Vasconcelos-Santos DV; Habot-Wilner Z; Coupland SE; Pulido JS; Smith J; Thorne JE; Zierhut M;
    Ocul Immunol Inflamm; 2021 Apr; 29(3):507-520. PubMed ID: 34009095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
    Moreno DF; López-Guerra M; Paz S; Oliver-Caldés A; Mena MP; Correa JG; Battram AM; Osuna M; Rivas-Delgado A; Rodríguez-Lobato LG; Cardús O; Tovar N; Cibeira MT; Jiménez-Segura R; Bladé J; Rosiñol L; Colomer D; Fernández de Larrea C
    Br J Haematol; 2023 Jan; 200(2):187-196. PubMed ID: 36210485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.
    Hamadeh F; MacNamara SP; Aguilera NS; Swerdlow SH; Cook JR
    Mod Pathol; 2015 Apr; 28(4):564-74. PubMed ID: 25216226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].
    Ren Y; Zhou BQ; Xu Y; Fu CC; Shen HJ; Ding ZX; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1054-1059. PubMed ID: 28088969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.
    King RL; Gonsalves WI; Ansell SM; Greipp PT; Frederick LA; Viswanatha DS; He R; Kyle RA; Gertz MA; Kapoor P; Morice WG; Howard MT
    Am J Clin Pathol; 2016 Jun; 145(6):843-51. PubMed ID: 27329639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.